(NASDAQ:ANGN) ANGION BIOMEDICA CORP, rallied at the end of the day today for a 18% gain in news of the annual shareholders meeting and recent H.C. Wainwright “Buy” rating of up to $32.00

HC Wainwright has removed Angion Biomedica Corp’s (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating.

In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data.

The analyst believes that the Company is better positioned than the market appears to think, particularly in light of the Company’s currently negative enterprise value of $(32.56) million, as per Benzinga Pro.

It possesses an extensive pipeline of assets beyond ANG-3777, which the market does not appear to be taking into consideration, analysts note.

Editor has purchased shares in this company.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.